Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical needs, today announced that AbbVie communicated during their third-quarter financial results1 on Friday October 28th, that they decided to stop the development of cedirogant (ABBV-157), an oral RORg inverse agonist jointly discovered by Inventiva and AbbVie for the treatment of autoimmune diseases, following the analysis of a recently concluded nonclinical toxicology study.
The Company’s cash runway, including the expected $12 million upfront payment from Sino Biopharm and the €25 million from the EIB credit facility2, is not impacted by the discontinuation of the cedirogant clinical program and should allow to fund as previously announced operations through Q4 20233. Inventiva’s R&D capabilities and objectives remain unaltered.
https://finance.yahoo.com/news/inventiva-provides-development-cedirogant-abbvie-070000880.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.